康艾注射液联合化疗治疗晚期肺癌55例疗效观察  

Clinical efficacy of Kang'ai injection combined with chemotherapy in treatment of advanced lung cancer: An observation of 55 cases

作　　者：张盛奇[1] 林丽芳[1] 郑泓斌[1] 邱希辉[1] 庄晓文[1] 陈志明[1] 

机构地区：[1]汕头大学医学院附属肿瘤医院中西医结合科,广东汕头515031

出　　处：《中国医药科学》2014年第12期62-64,共3页China Medicine And Pharmacy

摘　　要：目的观察康艾注射液联合化疗治疗晚期肺癌的近期疗效、生活质量的改善和减轻化疗引起的不良反应。方法选择55例晚期肺癌患者随机分成治疗组30例、对照组25例。治疗组给予化疗加康艾注射液治疗，对照组给予单纯化疗。结果治疗组和对照组的近期总有效率分别为60％和56％，两组比较，差异无统计学意义（P〉0．05）；治疗后kps评分，治疗组和对照组生活质量改善率分别为90％和72％，两组比较，差异有统计学意义（P〈0．05）；消化道反应率0-1度，治疗组为90％，明显高于对照组72％；2-4度为10％明显低于对照组28%（P〈0．05）。治疗组2—4度的骨髓功能抑制率为30％，明显低于对照组44％（P〈0．05）。不良反应发生率对照组明显多于治疗组。结论非小细胞肺癌用康艾注射液联合化疗与单纯化疗比较疗效相当，并且可以提高患者生活质量，减轻不良反应，值得临床广泛推广。Objective To discuss improvement of term clinical efficacy, quality of life and relief of adverse reactions caused by chemotherapy of Kang＇ai injection combined with chemotherapy in treatment of advanced lung cancer. Methods Selected 55 cases with advanced lung cancer were randomly divided into treatment group with 30 cases and control group with 25 cases. Treatment group were treated with Kang＇ai injection combined with chemotherapy, and control group received Chemotherapy. Results term clinical efficacy of two groups were 60% and 56%, without significant different between two groups（P 〉 0.05）; kps score after treatment, improvement rates of quality of life of treatment and control group were 90% and 72%, with significant different between two groups; Gastrointestinal response rate from 0 to 1 degree, treatment group was 90%, which was higher than 72% of control group; Gastrointestinal response rate from 2 to 4 degree of treatment group was lower than 28% of control group （P 〈 0.05）. 2 to 4 degree of bone marrow suppression rate of treatment group was 30%, which was lower than 44% of control group （P 〈 0.05）. Adverse reaction rate of control group was higher than treatment group （P 〈 0.05）. Conclusion Kang＇ai injection combined with chemotherapy in treatment of non-small cell lung cancer shows fairly efficacy of chemotherapy with chemotherapy Kang＇ai injection, and can improve quality of life, relief adverse reactions, worthy of cilinical promotion.

关 键 词：康艾注射液 化疗 晚期肺癌 

分 类 号：R734.2[医药卫生—肿瘤]